Innovex International SAS

What Innovex International SAS does

Innovex International SAS is a Bogota-headquartered pharmaceutical solutions provider serving emerging markets across Latin America, Central America, and the Caribbean. The company operates as the LATAM commercialization arm of RTM Healthcare Group, an India-based pharmaceutical conglomerate, and is publicly listed on NYSE under ticker INVX. Its portfolio spans 381+ finished pharmaceutical products across 11 therapeutic areas including oncology, cardiovascular, CNS, dermatology, and hematology, alongside innovator and orphan drugs targeting rare diseases, and a full regulatory services platform covering dossier preparation (CTD/eCTD/ACTD), pharmacovigilance, stability and bioequivalence studies, translation services in English/Spanish/Portuguese, and GDP/GMP-compliant temperature-controlled supply chain with full batch traceability.

The business model combines B2B product distribution (finished generics and orphan drugs sold to hospitals, clinics, and healthcare providers) with professional regulatory and pharmacovigilance services for pharmaceutical companies seeking market access in LATAM jurisdictions. Go-to-market is enterprise field sales combined with event-driven thought leadership at industry conferences and KOL speaker programs targeting healthcare professionals. Customers fall into three primary segments: pharmaceutical companies needing regulatory and commercialization support, healthcare providers requiring specialty generics and orphan drug access, and rare disease patients reached through named special programs. Pricing is quote-based and negotiated per product, country, and volume with no public list pricing.

The company is in active expansion mode: it completed the acquisition of TCO Group in Norway in August 2026, executed a $143.55M secondary stock offering on NYSE the same month, and operates parallel subsidiaries Zeal Healthcare (LATAM), ARM Life Sciences (Middle East), and RPW (international business). Q2 2026 reported revenue was $244.90M with EPS of $0.36, both exceeding analyst consensus, and management has signaled forward interest in biosimilars and vaccines alongside its traditional specialty generics focus.

Name

Innovex International SAS

Legal name

Innovex International SAS

Website

https://innovexinternational.com

Company type

Public

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Short description

Innovex International SAS is a Bogota-headquartered pharmaceutical company (NYSE: INVX) and LATAM arm of RTM Healthcare Group that distributes 381+ specialty generics and orphan drugs across 22+ countries and provides regulatory, pharmacovigilance, and supply chain services to pharmaceutical manufacturers, hospitals, and rare disease patients.

Ownership category

akta.pro rank

Headquarters

HQ city

Bogota

HQ country

Colombia

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Supply Chain, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Finished Pharmaceutical Products: Sale of diverse finished pharmaceutical products across 11 therapeutic areas including oncology, urology, gynaecology, NSAID, dermatology, immunology, CNS, cardiovascular, gastrointestinal, nephrology, and hematology. Revenue is generated through direct sales to healthcare providers and distributors in LATAM markets.
2. Orphan Drugs / Innovator Products: Specialized medications targeting rare diseases and niche medical needs, addressing conditions with limited treatment options. Revenue from import and distribution of orphan drugs to healthcare providers and medical institutions.
3. Regulatory Services: Comprehensive regulatory support including product registration, plant inspection services, legal/IP/trademark services, and translation services in English, Spanish, and Portuguese. Provided as professional services to pharmaceutical companies.
4. Special Import and Supply Chain Services: Sourcing, importing, and delivering pharmaceutical products with fully documented supply chain. Services include resolving supply shortages and international product research through the company's global network.
5. Stability and BA/BE Studies: Bioequivalence and bioavailability studies for demonstrating therapeutic equivalence of generic drugs, conducted for national and international markets. Also includes comprehensive stability studies across all therapeutic areas.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Innovex International SAS provides pharmaceutical distribution, regulatory affairs, pharmacovigilance, and supply chain services for emerging markets in Latin America, Central America, and the Caribbean. The company distributes a portfolio of 381+ finished pharmaceutical products across 11 therapeutic areas and specializes in sourcing orphan drugs for rare diseases. Its service offerings cover product registration, CTD/eCTD dossier preparation, bioequivalence and stability studies, multilingual translations, and GDP/GMP-compliant temperature-controlled logistics.

Product overview

Innovex International SAS is a pharmaceutical solutions provider offering a comprehensive portfolio of finished pharmaceutical products, innovator drugs including orphan drugs, and regulatory services. The core offerings include Finished Products spanning 11 therapeutic areas (Oncology, Urology, Gynaecology, NSAID, Dermatology, Immunology, CNS, Cardiovascular, Gastrointestinal, Nephrology, Hematology), Innovator-Drugs/Orphan Drugs for rare diseases, and Regulatory Services encompassing product registration, pharmacovigilance, translations, stability/BA-BE studies, CTD dossier preparation, and special import supply chain services. The company operates as part of RTM Healthcare Group with headquarters in Colombia serving emerging markets across Latin America and the Caribbean.

Differentiator

Problem solved

Functional benefit

Products and services

• Finished Pharmaceutical Products A diverse range of finished pharmaceutical products distributed across 11 therapeutic areas including Oncology, Urology, Gynaecology & Obstetrics, NSAID, Dermatology, Immunology, CNS, Cardiovascular, Gastrointestinal, Nephrology, and Hematology, supplied to healthcare providers and distributors in LATAM markets.
• Innovator Drugs / Orphan Drugs Specialized innovator products including orphan drugs that target rare diseases and conditions affecting small patient populations, often lacking adequate treatment options, imported and distributed to healthcare providers and medical institutions.
• Regulatory Services Comprehensive regulatory support including product registration, importation, distribution, plant inspection services, special imports for orphan drugs, named special programs, legal/IP/trademark services, and translation services in English, Spanish, and Portuguese, provided to pharmaceutical companies seeking LATAM market access.
• Stability and BA/BE Studies Comprehensive stability studies for pharmaceutical products and bioequivalence/bioavailability studies demonstrating therapeutic equivalence of generic drug products compared to brand-name counterparts, conducted for national and international markets.
• CTD Dossier Preparation Service Preparation of CTD, eCTD, ACTD, and other dossier types meeting EU, US, and other regulated market standards, including semi-regulated and unregulated markets, for pharmaceutical companies seeking market registration.
• Special Import and Supply Chain Services Sourcing, importing, and delivering pharmaceutical products with a fully-documented supply chain, resolving supply shortages, international product research, and maintaining product integrity with temperature-controlled containers compliant with GDP and GMP regulations.
• Translation Services Professional translation services for dossiers and technical or legal documents for LATAM country regulations into Spanish and Portuguese languages, supporting pharmaceutical companies in regulatory submissions.
• Pharmacovigilance Services Activities focused on detection, evaluation, understanding, and prevention of adverse events or problems associated with medicines, establishing safety profiles for marketed products, provided to pharmaceutical companies with products in LATAM markets.

Quantifiable outcome

• Second-quarter revenue of $244.90 million exceeded analyst forecast of $241.58 million
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core and minor.

• TCO GroupcoreStrategic or Co-development Partner · 10 August 2026Innovex International completed the acquisition of TCO Group in Norway as of August 2026, representing a strategic expansion of the company's capabilities and geographic footprint into the Norwegian market. This acquisition strengthens the group's international operations and is part of a broader transformation within the RTM Healthcare Group.
• Zeal HealthcarecoreStrategic or Co-development Partner · 1 January 2024Zeal Healthcare was established in early 2024 as a strategic partnership with Innovex International to serve the Latin American market, focusing on pharmaceutical product commercialization and distribution across LATAM countries.
• RPW (RTM Pharma Worldwide)coreChannel Partner/ Reseller/ Distributor · 1 January 2024RPW was founded in 2024 as part of the RTM Healthcare Group structure to handle operations and international business, serving as a key distribution and operations partner for Innovex International's global expansion.
• ARM Life SciencesminorStrategic or Co-development Partner · 1 January 2024ARM Life Sciences was founded in 2024 to establish and manage Innovex International's operations in the Middle East region, representing geographic expansion beyond the core LATAM markets.
• International Regulatory Bodies and Accredited PartnersminorOthersThe company's accreditations are backed by the most important regulators worldwide, with international allies providing regulatory support and compliance verification. Specific regulatory body names are not individually listed but are displayed as accreditations on the website.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Market position

Competitive moat4 records

Customer concentration

• LinkedInlinkedin.com/company/innovex-international-sas

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Innovex International SAS